Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas

Inclusion Criteria: * Patients with histologically confirmed solid tumors or lymphomas. * Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy. * One or more tumors measurable on radiograph or CT scan, or evaluable disease (e.g., malignant ascites). * Karnofsky performance status of greater than or equal to 70. * Life expectancy of at least 3 months. * Age at least 18 years. * Patients must have central IV access, or agree to the insertion of a central IV line. * Normal oxygen saturation by pulse oximetry on room air * A negative pregnancy test (if female). * Acceptable liver function as evaluated by laboratory results * Acceptable renal function as evaluated by laboratory results * Acceptable hematologic status as evaluated by laboratory results * No clinically significant urinalysis abnormalities * Acceptable coagulation status as evaluated by laboratory results * Fertile men and women must use effective contraceptive methods during the study. Exclusion Criteria: * Seizure disorders requiring anticonvulsant therapy. * Known brain metastases (unless previously treated and well controlled for a period of greater than or equal to 3 months). * Severe chronic obstructive pulmonary disease with hypoxemia, or an uncorrectable pulmonary compromise. * Major surgery, other than diagnostic surgery, within 4 weeks prior to the first dose of test drug. * Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. * Pregnant or nursing women. * Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within one month prior to study entry (6 weeks for nitrosoureas or Mitomycin C). * Unwillingness or inability to comply with procedures required in this protocol. * Known infection with HIV, hepatitis B, or hepatitis C. * Clinically significant bleeding event within the last 3 months, unrelated to trauma, or underlying condition that would be expected to result in a bleeding diathesis. * Patients who are currently receiving any other investigational agent. * Patients who have exhibited allergic reactions to a similar structural compound (e.g., fluoroquinolones, biological agent or formulation.